Moderna (MRNA) Has a Gigantic Year-over-year Revenue Growth


The MRNA stock price fluctuated between $336 and $351.22 throughout the trading session with the volume trading being 10M shares, which represented a negative variation when compared to the three months average volume of 13M shares.

The share price of Moderna, Inc. (NasdaqGS:MRNA) dipped -1.05% to close Friday’s market session at $345.64, lower as compared to yesterday’s close which brings the market valuation of the company to $138.78B.

The 52-week high for the Moderna, Inc.’s shares is $362.00. That puts it -4.52% from that peak but still an impressive gain since the share price dropped to a 52-week low of $54.21, while the S&P 500’s share price change was of N/A.

The company currently has a 231.66 P/E ratio and a price target of $184.92.

What does the trading volume tell us about the MRNA stock?

During the last trading session, Moderna, Inc. (NasdaqGS:MRNA) has seen decay in its daily volume. The daily volume was of 13M, while in the last 10 days the average was 35.36M and last three months – 12.95M.
The decreasing interest in the MRNA stock from the investors is helping to drive the stock price down.

Shrinking short interest

The Moderna, Inc.’s shares are seeing a decreasing short interest compared to the previous month. As of today, there are 11.83M shares being shorted which translates into 1.27 of a short ratio for MRNA, while in the previous month the shorted shares were 12.94M.

Moderna, Inc. (NasdaqGS:MRNA) financials

With a market cap of 138.78B, Moderna, Inc. holds a total cash of $7.74B that translates into $19.26 per share, while the total debt is of $279M.

The company has seen a decrease in the revenue with a year-over-year quarterly revenue growth percentage of 24,112.50%. The current revenue is of $2.73B that is $6.95 per share.
This is a not so good sign for the future.